Our vaccine pipeline

Our vaccine pipeline

At Valneva, we take a specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solution.

Our current vaccine portfolio is composed of a number of highly differentiated vaccine candidates that are designed to provide preventative solutions to diseases with high unmet need. Our goal is to develop vaccine candidates that are first-, best- or only-in-class class and address unmet needs in infectious diseases. Our aim is to either develop them for future commercialization in-house or through and with partners.

Clinical candidates

• VLA1553 is a vaccine candidate which was approved by the U.S. FDA under the brand name IXCHIQ^® in November 2023 and since, in Europe, the United Kingdom and Canada. It is indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older; in Europe it was recently granted marketing authorization for individuals 12 years of age and older. As of April 2025, it was also granted marketing authorization for those 18 years and older in Brazil, the first authorization in an endemic country. VLA1553 is still undergoing several clinical trials with a view to support additional marketing approvals and potential label extensions.
• VLA15 is a Phase 3 vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease, under development in collaboration with Pfizer, and it is the only active vaccine candidate against Lyme disease currently undergoing late-stage clinical trials. VLA15 targets the six most prevalent serotypes, or variations, of Borrelia in the United States, where approximately 476,000 people are diagnosed with Lyme disease each year and in Europe, where at least a further 200,000 cases occur annually. First data readout for Lyme disease Phase 3 VALOR study expected at the end of 2025.
• VLA1601 is a Phase 1 vaccine candidate targeting the Zika virus (ZIKV), a mosquito-borne viral disease whose transmission has been reported in 89 countries and territories and persists in several countries in the Americas and other endemic regions. There are no preventive vaccines or effective treatments available and, as such, Zika remains a public health threat. VLA1601 is being developed on the original manufacturing platform of Valneva’s licensed Japanese Encephalitis vaccine IXIARO^®, which was further optimized to develop our inactivated, adjuvanted COVID-19 vaccine VLA2001, the first COVID-19 to receive a standard marketing authorization in Europe.

Pre-clinical candidates

• VLA2112 is a vaccine candidate targeting Epstein-Barr Virus (EBV), also known as human herpesvirus 4, and is a member of the herpes virus family. It is found all over the world and is one of the most common human viruses. Valneva expects to conduct initial pre-clinical proof of concept by the end of 2024.